Daljit Singh Aurora files SEC Form 4 disclosures for Neumora Therapeutics, Inc.. They have made 3 open-market trades across 1 company since 2025, most recently 2026-08-21.
CIK 0001793971
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| NMRA | 21,055 | $12K |
Shares reported on the most recent Form 4, priced at the 2026-08-21 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NMRA | SELL | 2026-08-20 | 2026-08-21 | $1.53 | $270K | -14.1% | -56.7% | — |
| NMRA | SELL | 2026-08-17 | 2026-08-19 | $1.55 | $432K | -17.6% | -55.1% | — |
| NMRA | SELL | 2026-02-17 | 2026-02-19 | $3.56 | $22K | -12.1% | -29.0% | -50.3% |
| NMRA | SELL · 10b5-1 | 2025-11-11 | 2025-11-13 | $2.68 | $615K | -13.8% | -24.9% | +14.9% |
| NMRA | SELL · 10b5-1 | 2025-02-18 | 2025-02-20 | $1.68 | $14K | -18.0% | -30.2% | -56.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.